X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Towards High-Performing Health Systems / (2004)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_9958089578602883
    Format: 1 online resource (133 p.)
    ISBN: 1-280-17161-8 , 9786610171613 , 92-64-01556-6
    Series Statement: The OECD Health Project,
    Content: This volume offers a synthesis of findings from recent OECD studies undertaken as part of the three-year Health Project, an initiative geared towards answering many of the key questions facing today’s health policy makers. It provides information and analysis on a wide variety of topics, such as new and emerging health-related technologies, long-term care, private health insurance, health-care cost control, equity of access across income groups, health workforce planning and productivity, and waiting times for elective surgery. Building on international experience and grounded in new data on cross-country differences, this report offers an up-to-date map of the road to performance improvement.
    Note: Description based upon print version of record. , Foreword; Preface; Table of contents; Executive summary; Introduction; Chapter 1 - Better health through better care: the quest for quality; Chapter 2 - Access to care: the quest to improve and maintain; Chapter 3 - Satisfied patients and consumers: the quest for greater responsiveness; Chapter 4 - Health-care spending: the quest for affordable costs and sustainable financing; Chapter 5 - Increasing value for money in health systems: the quest for efficiency; Conclusions from the OECD Health Project: promising approaches for improving health-system performance; Bibliography; Also available , English
    Additional Edition: ISBN 92-64-01555-8
    Language: English
    URL: Volltext
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Online Access
    Stabi Berlin
    HU Berlin
    FU Berlin
    UB Potsdam
    Charité
  • 2
    Online Resource
    Online Resource
    Health-Care Systems : Lessons from the Reform Experience (2003)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_9958075073902883
    Format: 1 online resource (98 pages)
    Content: This study presents a broad overview of health-system reforms in OECD countries over the past several decades. Reforms are assessed according to their impact on the following policy goals: ensuring access to needed health-care services; improving the quality of health care and its outcomes; allocating an "appropriate" level of pubic sector and economy-wide resources to health care (macroeconomic efficiency); and ensuring that services are provided in a cost-efficient and cost-effective manner (microeconomic efficiency).While nearly all OECD countries have achieved universal coverage of health-care risks, initiatives to address persistent disparities in access are now being undertaken in a number of countries. In light of new evidence of serious problems with health-care quality, many countries have recently introduced reforms intended to improve this, but it is too soon to generalise as to the relative effects of alternative approaches. A variety of instruments aimed at ... This paper is also published under OECD Economics Department Working Papers Series.
    Language: English
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
    Charité
  • 3
    Online Resource
    Online Resource
    Towards High-Performing Health Systems : Policy Studies (2004)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_9958073390002883
    Format: 1 online resource (333 p.)
    ISBN: 1-280-17162-6 , 9786610171620 , 92-64-01560-4
    Series Statement: The OECD Health Project,
    Content: This series of seven policy studies were the source material for the synthesis report of The OECD Health Project, Towards High-Performing Health Systems.  They cover lessons from experience in health system reform, improving the technical quality of health care, income-related inequality in health care, matching supply with demand for physicians and nurses, excessive waiting times, costs and benefits of private health insurance, and ageing-related spending projections.
    Note: At head of title: The OECD health project. , Foreword; Table of Contents; Preface; Introduction; Chapter 1. Health-System Reform: Lessons from Experience; Chapter 2. Monitoring and Improving the Technical Quality of Medical Care: A New Challenge for Policy Makers in OECD Countries; Chapter 3. Income-related Inequality in the Use of Medical Care in 21 OECD Countries; Chapter 4. Matching Supply with Demand for the Services of Physicians and Nurses; Chapter 5. Tackling Excessive Waiting Times for Elective Surgery; Chapter 6. Private Health Insurance in OECD Countries: The Benefits and Costs for Individuals and Health Systems , Chapter 7. Ageing-related Spending Projections on Health and Long-term Care , English
    Additional Edition: ISBN 92-64-01559-0
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    HU Berlin
    FU Berlin
    Charité
  • 4
    Online Resource
    Online Resource
    Towards high-performing health systems / (2004)
    Paris, France :OECD,
    Details
    UID:
    almahu_9949914430802882
    Format: 1 online resource (129 pages) : , illustrations.
    ISBN: 9789264015562 (e-book)
    Series Statement: OECD health project
    Additional Edition: Print version: Docteur, Elizabeth. Towards high-performing health systems. Paris, France : OECD, c2004 ISBN 9789264015555
    Language: English
    Keywords: Electronic books.
    URL: Click to View
    URL: OECDiLibrary
    URL: OECDiLibrary
    URL: OECDiLibrary
    URL: OECDiLibrary
    URL: Full text available from SourceOECD
    URL: Publisher description
    URL: To read this title online, search for it in SourceOECD
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    HU Berlin
    HPol Brandenburg
  • 5
    Online Resource
    Online Resource
    Pharmaceutical Pricing and Reimbursement Policies in Switzerland / (2007)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047933446
    Format: 1 Online-Ressource (61 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Health Working Papers
    Content: This paper examines aspects of the policy environment and market characteristics of the Swiss pharmaceutical sector, and assesses the degree to which Switzerland has achieved certain policy goals. In Switzerland, pharmaceutical spending has not been growing faster than health expenditure as a whole, as has been the case in many other OECD countries. Swiss pharmaceutical spending per capita and as a share of GDP is modest by OECD standards. This in part reflects relatively low levels of pharmaceutical consumption, given that public prices are among the highest in Europe and the Swiss tend to be early adopters of new pharmaceutical products. Switzerland's regulation of prices for reimbursed drugs, based on referencing across countries and within the therapeutic class for products with comparators, appears to result in prices lower than what would be obtained absent regulation. Although ex-manufacturer prices are somewhat high relative to other European countries, recent reforms have reduced the differential. While costs are under control, Switzerland has scope to improve the cost-effectiveness of its expenditures in the pharmaceutical area. Generic penetration of the market is increasing but falls short of what has been achieved elsewhere and the prices of generic products are higher than what is found in other countries. Relatively high mark-ups over ex-factory prices suggest that the distribution chain is a source of further potential efficiencies, although high costs could also reflect characteristics of the Swiss economy...
    Language: English
    DOI: 10.1787/136157357151
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
  • 6
    Online Resource
    Online Resource
    Pharmaceutical Pricing and Reimbursement Policies in Mexico / (2007)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047933249
    Format: 1 Online-Ressource (66 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Health Working Papers
    Content: This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals
    Language: English
    DOI: 10.1787/302355455158
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
  • 7
    Online Resource
    Online Resource
    The US Health System : An Assessment and Prospective Directions for Reform (2003)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047937130
    Format: 1 Online-Ressource (63 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Economics Department Working Papers
    Content: This paper assesses the performance of the United States health system in an international context and discusses potential directions for reform. The US health system is unique among OECD countries in its heavy reliance on the private sector for both financing and delivery of health care. The public sector plays a not-insignificant role, providing coverage for the elderly, disabled and poor, and spending as much on health as a share of GDP as is spent in total by many OECD countries. The system is considered highly flexible, capable of evolving quickly to address the changing preferences of consumers and the incentives put in place by the requirements of payers and government regulation. It is also characterised by excellent access by the insured population to the latest advances in medical technology. However, 14 per cent of Americans lack insurance coverage, and the decentralised, multi-payer approach to financing and regulation provides relatively few levers to control ...
    Language: English
    DOI: 10.1787/768340075526
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
  • 8
    Online Resource
    Online Resource
    Pharmaceutical Pricing and Reimbursement Policies in Canada / (2006)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047931732
    Format: 1 Online-Ressource (90 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Health Working Papers
    Content: This paper describes and assesses pharmaceutical pricing and reimbursement policies in Canada, considering them in the context of the broader policy and market environment in which they operate, and investigating their role in contributing to Canada's achievements in meeting a range of objectives relating to the pharmaceutical policy. The federal government regulates prices of patented pharmaceutical products with the objective of protecting consumers against excessive prices. Regulation has very likely been responsible for bringing Canada's prices for patented medicines roughly in line with European comparators. Prices of generic products, which are not regulated, are relatively high although high...
    Language: English
    DOI: 10.1787/346071162287
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
  • 9
    Online Resource
    Online Resource
    Pharmaceutical Pricing and Reimbursement Policies in Slovakia / (2008)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047934395
    Format: 1 Online-Ressource (55 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Health Working Papers
    Content: This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than it does in any other OECD country, and the share of national income going to pharmaceuticals is exceeded only in Hungary. Although its relatively low national income is a partial explanation for Slovakia's status in this respect, this review finds that Slovakia has scope to reduce its expenditures and the rapid rate of growth in its pharmaceutical spending. Financing of pharmaceutical expenditure in Slovakia rests more heavily on the public sector than is typical in the OECD, with out-of-pocket spending accounting for just a quarter of total expenditure. The effectiveness of international price referencing in limiting Slovak prices for on-patent pharmaceutical products is questionable. For products that have gone off-patent and for those with similar chemical structure, a reference-pricing scheme and competition among generic alternatives results in effective price control, although incentives for generic substitution are weak (for patients) and misaligned (for pharmacists). When deciding whether a drug will be reimbursed through the social insurance scheme, the cost-effectiveness of new pharmaceuticals is not assessed. On the other hand, certain policy goals have been achieved. The accessibility and availability of medicines--including the most innovative products--is good; affordability is supported by relatively low average co-payment levels. While more expensive drugs usually have higher cost-sharing, drugs are not excluded from coverage on affordability grounds
    Language: English
    DOI: 10.1787/244264621247
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
  • 10
    Online Resource
    Online Resource
    Pharmaceutical Pricing and Reimbursement Policies in Germany / (2008)
    Paris :OECD Publishing,
    Details
    UID:
    almafu_BV047931337
    Format: 1 Online-Ressource (65 Seiten) ; , 21 x 29.7cm.
    Series Statement: OECD Health Working Papers
    Content: This paper describes pharmaceutical pricing and reimbursement policies in Germany, considering them in the broader environment in which they operate, and assesses their impact on the achievement of a number of policy goals. Pharmaceutical coverage is comprehensive, with a high level of public funding, and ensures access to treatments. However, recent increases in out-of-pocket payments may impair affordability for the poorest part of the population. Germany does not regulate ex-manufacturer prices of pharmaceuticals at market entry (though distribution margins are regulated for reimbursed drugs). On the other hand, maximum reimbursement amounts (known as reference prices) are set for products which can be clustered in groups of equivalent (generic) or comparable products (...)
    Language: English
    DOI: 10.1787/228483137521
    URL: Volltext  (kostenfrei)
    URL: Volltext  (kostenfrei)
    URL: Volltext  (URL des Erstveröffentlichers)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Online Resource
    Fulltext
    Fulltext
    FU Berlin
    EUV Frankfurt
Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages